For instance, a phase II clinical trial study that used PROSTVAC [an active immunotherapy vaccine that contains prostate-specific antigen (PSA)] and GM-CSF in a group of men with metastatic castration-resistant PC showed an increased survival of patients (109). This evidence concerns the gene CSF2 and pachyonychia congenita.